• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:07:33 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRX alert in real time by email
    SC 13G/A 1 tm216476d48_sc13ga.htm SC 13G/A

     

     

     

    CUSIP No: 79400X107

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ______________________

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Salarius Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    79400X107

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 79400X107

     

      (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      804,347
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      804,347
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        804,347
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.1%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 79400X107

     

      (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      804,347
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      804,347
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        804,347
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.1%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 79400X107

     

    Item 1.

     

    (a)    Name of Issuer

     

       Salarius Pharmaceuticals, Inc. (the “Company”)

     

    (b)   Address of Issuer’s Principal Executive Offices

     

       2450 Holcombe Blvd., Suite X, Houston, TX 77021

     

    Item 2(a).      Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).      Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).      Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)       Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)       CUSIP Number

     

    79400X107

     

     

     

     

    CUSIP No: 79400X107

     

    Item 3.           If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.           Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 19,843,866 Shares outstanding as of November 9, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.           Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     

     

     

    CUSIP No: 79400X107

     

    Item 6.           Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.           Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.           Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.           Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.         Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 79400X107

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc. pursuant to a Limited Power   By: /s/  Brian Sopinsky
    of Attorney, a copy of which was previously filed   Name:  Brian Sopinsky
      Title:    Secretary

    By: /s/  Brian Sopinsky  
    Name:  Brian Sopinsky  
    Title:    Secretary  

     

     

     

     

    CUSIP No: 79400X107

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed 

     

     

    Get the next $SLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLRX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    8/25/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

      CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therapeutics, announced that a series of antiviral drug candidates previously designed by its IMP3ACT™ platform to be broadly effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles and Nipah viruses. As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) signed a definitive merger agreement pursuant to which Decoy will merge with a wholly owned subsidiary of Salarius, subject to satisfaction of th

      3/26/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

      Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates expected later this year from the MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today repor

      3/24/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      11/14/24 4:38:31 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

      SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/14/24 3:54:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/13/23 4:30:18 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Arthur David J.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      4/12/24 4:50:27 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rosenblum Mark J

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:37:10 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcvicar William K.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:29:33 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      3/11/22 6:32:47 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      8/25/21 6:10:11 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.

      PRE 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/15/25 5:18:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.

      DEF 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/15/25 5:03:13 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Salarius Pharmaceuticals Inc.

      10-Q - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/14/25 5:02:39 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

      HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

      2/3/22 7:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Financials

    Live finance-specific insights

    See more
    • Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

      HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

      12/8/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

      60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

      12/1/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

      8/8/22 8:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care